Nimita Limaye

About Dr Nimita Limaye

Dr Nimita Limaye has over twenty years of experience working across the Pharma CRO industry, playing key leadership roles at companies such as Quintiles, TCS, SIRO, Altana Pharma, Cadila Healthcare, etc. She is also the past chair of the Society of Clinical Data Management (SCDM).

Mar 2018

The Three Biggest Challenges in RBM Related to Key Risk Indicators
Gallery
The Three Biggest Challenges in RBM Related to Key Risk Indicators

Blog

The Three Biggest Challenges in RBM Related to Key Risk Indicators

By Dr Nimita Limaye|2020-10-11T20:37:30+02:00March 14, 2018|Blog|Comments Off on The Three Biggest Challenges in RBM Related to Key Risk Indicators

Our online KRI (Key Risk Indicator) survey indicated that finding the right calculation method seems the most challenging aspect of the application of KRIs. In addition our survey showed that the vast majority (> 95%) makes use of KRIs. Do these results surprise you?